Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of Ataluren (PTC124) for Nonsense-Mutation-Mediated Hemophilia A and B
2010-020224-22Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ataluren in hemophilia A and hemophilia B (HB), sponsored by PTC Therapeutics, Inc. Primary endpoint: Plasma FVIII/FIX activity response. Started Jul 2010; status: completed.
02
Drugs
ataluren
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2010-020224-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020224-22.